Overview
Shuyin Information Technology is an AI drug research and development services provider.
Funding
Amounts as reported; USD estimates shown only when they matchListed 2 funding records.
No chartable funding estimates yet.
2 listed records lack a clear date or positive USD estimate for the chart.
| Date | Amount | Investors | Sources |
|---|---|---|---|
| Apr 29, 2026 | Tens of millions of US dollars · Pre-Series A | 上海大零号湾策源二号创业投资合伙企业（有限合伙）, 上海大零号湾策源创业投资合伙企业, 嘉必优生物产业投资有限公司, 广东康容药业股份有限公司, 赣州国惠润信创业投资基金 | No source link |
Evidence Shuyin Zhike raises tens of millions of USD in Pre-A fundingOn 2026/4/29, Xiniu Data reported that Shuyin Zhike completed Pre-A funding worth tens of millions of USD. Cabio Biological Industry Investment (Wuhan) Co., Ltd. led the round, with other investors including Guangdong Kangrong Pharmaceutical Co., Ltd., Shanghai Grand NeoBay Ceyuan Venture Investment Partnership (Limited Partnership), and Ganzhou Guohui Runxin Venture Capital Fund (Limited Partnership). The company provides AI drug discovery services. Translated source brief, not a quotation. Check the original before citing. Sources · 0
上海大零号湾策源二号创业投资合伙企业（有限合伙）, 上海大零号湾策源创业投资合伙企业, 嘉必优生物产业投资有限公司, 广东康容药业股份有限公司, 赣州国惠润信创业投资基金 | |||
| Sep 8, 2022 | Undisclosed · Strategic | Yunqi Capital | No source link |
Evidence No source brief is attached to this record. Sources · 0
| |||
Select ▸ on a row to see its source brief and links.
Valuation
Amounts as reported; USD estimates shown only when they matchListed 2 valuation records.
No chartable valuation estimates yet.
2 listed records lack a clear date or positive USD estimate for the chart.
| Date | Amount | Investors | Sources |
|---|---|---|---|
| Apr 29, 2026 | — · Pre-Series A | 上海大零号湾策源二号创业投资合伙企业（有限合伙）, 上海大零号湾策源创业投资合伙企业, 嘉必优生物产业投资有限公司, 广东康容药业股份有限公司, 赣州国惠润信创业投资基金 | No source link |
Evidence Shuyin Zhike raises tens of millions of USD in Pre-A fundingOn 2026/4/29, Xiniu Data reported that Shuyin Zhike completed Pre-A funding worth tens of millions of USD. Cabio Biological Industry Investment (Wuhan) Co., Ltd. led the round, with other investors including Guangdong Kangrong Pharmaceutical Co., Ltd., Shanghai Grand NeoBay Ceyuan Venture Investment Partnership (Limited Partnership), and Ganzhou Guohui Runxin Venture Capital Fund (Limited Partnership). The company provides AI drug discovery services. Translated source brief, not a quotation. Check the original before citing. Sources · 0
上海大零号湾策源二号创业投资合伙企业（有限合伙）, 上海大零号湾策源创业投资合伙企业, 嘉必优生物产业投资有限公司, 广东康容药业股份有限公司, 赣州国惠润信创业投资基金 | |||
| Sep 8, 2022 | — · Strategic | Yunqi Capital | No source link |
Evidence No source brief is attached to this record. Sources · 0
| |||
Select ▸ on a row to see its source brief and links.
Revenue
Amounts as reported; USD estimates shown only when they matchNo revenue records are listed yet.
No revenue rows to list.
Team, products & investors
Explore
More Industry apps companies
Sources · 0Sources & provenance
English text is maintained separately from the original record. Consult the original source before citing a fact.
No source links are available for this profile.
Original source text
Names may use phonetic renderings when no English name is supplied. The original wording is retained below.
AI药物研发服务商 数因信科是一家AI药物研发服务商